Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
基本信息
- 批准号:10704557
- 负责人:
- 金额:$ 7.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-24 至 2024-08-23
- 项目状态:已结题
- 来源:
- 关键词:AffinityAgonistAlgorithmsBindingBinding SitesBioinformaticsBiological ModelsCellsClassificationCommunicationComplexCoupledCouplingCryoelectron MicroscopyCuesCyclic NucleotidesDataDefectDevelopmentDiseaseDoctor of PhilosophyDrug Binding SiteDrug DesignDrug TargetingElectrodesElectronic Medical Records and Genomics NetworkElectrophysiology (science)EquilibriumEvaluationExposure toFDA approvedFamilyFrequenciesFunctional disorderFutureGenomicsGoalsHCN1 channelHCN1 geneHeartHuman GenomeHuman bodyHyperactivityIndividualIon ChannelLinkLipidsLocationMeasurementMeasuresMethodsMolecular ConformationMutagenesisMutateMutationPathway AnalysisPharmaceutical PreparationsPhysiological ProcessesPopulationPositioning AttributePostdoctoral FellowPropofolProtein FamilyProtein IsoformsProteinsReactionRegulationRoleSequence AlignmentSeverity of illnessSignal TransductionSpecificityStructureStructure-Activity RelationshipTestingValidationanalogantagonistdesigndrug discoveryexperimental studygenomic predictorsinhibitorinterestmembermutantnanodiskneurotransmissionnew therapeutic targetnovelpain perceptionparticlepatch clamppractical applicationreceptorreconstitutionside effectsmall moleculestructural biologyvoltagevoltage clamp
项目摘要
PROJECT SUMMARY
Cyclic nucleotide modulated ion channels are a class of proteins that have important roles in many physiological
processes, including regulation of the heart, neuronal signaling, and pain perception. The discovery of new
drugs targeting different ion channels is notoriously difficult for a host of reasons, as the focus on traditional
orthosteric agonists and antagonists has been dominant. Overall, this proposal unifies genomic, functional, and
structural methods to reveal how specific allosteric interactions govern mechanistic function. The ability to detect
and isolate the function of networks of allosteric interactions can provide a more focused approach in the design
of allosteric drugs for cyclic nucleotide modulated channels. In the first aim, I will identify and classify allosteric
networks using coevolution analysis. Mutagenesis and quantitative electrophysiology measurements will be
used to probe how different residue positions contribute to requisite energetic coupling in channel gating. Next,
we will use this unique information to obtain novel channel transition states. The overall goal of this aim is to
define allosteric networks that functionally regulate cyclic nucleotide modulated ion channels, experimentally
validate these networks functionally, and use this information to obtain difficult-to-resolve conformational states.
In the second aim, I will seek to uncover unknown binding sites for known allosteric modulators of cyclic
nucleotide modulated ion channels. Using cryoEM, we will determine the structure of channels in complex with
established allosteric modulators and define their interaction with the allosteric networks in aim 1. We will
validate the binding site using mutagenesis and two electrode voltage clamp. This aim will demonstrate feasibility
of drug design strategies targeting allosteric networks.
项目摘要
环核苷酸调节的离子通道是一类在许多生理过程中具有重要作用的蛋白质,
过程,包括心脏的调节,神经元信号传导和疼痛感知。发现新
由于许多原因,靶向不同离子通道的药物是众所周知的困难,因为传统的药物治疗方法的重点是治疗不同的离子通道。
正构激动剂和拮抗剂已经占主导地位。总的来说,这一提议将基因组、功能和
结构的方法来揭示如何具体的变构相互作用支配机械功能。检测能力
分离变构相互作用网络的功能可以提供一种更集中的设计方法,
用于环核苷酸调节通道的变构药物。在第一个目标中,我将识别和分类变构
使用协同进化分析的网络。突变和定量电生理学测量将
用于探测不同的残基位置如何在通道门控中对必需的能量耦合做出贡献。接下来,
我们将使用这种独特的信息来获得新的信道过渡态。这一目标的总体目标是
实验上定义了功能性调节环核苷酸调节离子通道的变构网络,
验证这些网络的功能,并使用这些信息来获得难以解析的构象状态。
在第二个目标中,我将寻求发现已知的环己基转移酶变构调节剂的未知结合位点。
核苷酸调节的离子通道。使用cryoEM,我们将确定通道的结构,
建立了变构调节剂,并在目标1中定义了它们与变构网络的相互作用。我们将
用诱变和双电极电压钳验证结合位点。这一目标将证明可行性
针对变构网络的药物设计策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Elizabeth Dione Kim其他文献
Elizabeth Dione Kim的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Elizabeth Dione Kim', 18)}}的其他基金
Identification of potential drug binding sites within allosteric networks in cyclic nucleotide modulated channels
环核苷酸调节通道变构网络内潜在药物结合位点的鉴定
- 批准号:
10537846 - 财政年份:2022
- 资助金额:
$ 7.18万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 7.18万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 7.18万 - 项目类别: